Jörg Schrader

2.4k total citations · 1 hit paper
52 papers, 1.6k citations indexed

About

Jörg Schrader is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Jörg Schrader has authored 52 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 36 papers in Epidemiology and 20 papers in Neurology. Recurrent topics in Jörg Schrader's work include Neuroendocrine Tumor Research Advances (34 papers), Lung Cancer Research Studies (23 papers) and Neuroblastoma Research and Treatments (20 papers). Jörg Schrader is often cited by papers focused on Neuroendocrine Tumor Research Advances (34 papers), Lung Cancer Research Studies (23 papers) and Neuroblastoma Research and Treatments (20 papers). Jörg Schrader collaborates with scholars based in Germany, Switzerland and United States. Jörg Schrader's co-authors include Daniel Benten, Alexander Quaas, Rebecca L. Aucott, Shaun Walsh, Stuart J. Forbes, John P. Iredale, M. van Deemter, Timothy T. Gordon‐Walker, Rebecca G. Wells and Paul Walter Schönle and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and PLoS ONE.

In The Last Decade

Jörg Schrader

49 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells

2010 568 citations Jörg Schrader, Daniel Benten et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jörg Schrader Germany	18	664	434	368	322	277	52	1.6k
Minoru Tanaka Japan	18	341 0.5×	775 1.8×	276 0.8×	94 0.3×	192 0.7×	31	1.8k
Elizabeth L. Buza United States	27	1.1k 1.6×	1.4k 3.3×	254 0.7×	134 0.4×	523 1.9×	48	2.9k
Christopher J. Hindley United Kingdom	18	386 0.6×	889 2.0×	221 0.6×	417 1.3×	56 0.2×	31	2.0k
Sarah Haylock‐Jacobs Canada	12	257 0.4×	366 0.8×	77 0.2×	186 0.6×	369 1.3×	20	1.2k
Matthias Mehling Switzerland	25	445 0.7×	977 2.3×	130 0.4×	151 0.5×	841 3.0×	47	2.7k
Yinyan Wang China	33	380 0.6×	662 1.5×	273 0.7×	60 0.2×	318 1.1×	145	3.3k
Masashi Urabe Japan	29	547 0.8×	2.2k 5.0×	308 0.8×	76 0.2×	267 1.0×	98	3.3k
Stephen Hunter United States	22	414 0.6×	773 1.8×	153 0.4×	259 0.8×	150 0.5×	49	2.0k
Michael Mosley United Kingdom	17	304 0.5×	701 1.6×	106 0.3×	92 0.3×	221 0.8×	39	1.8k
Ichiko Saotome United States	18	364 0.5×	1.2k 2.7×	286 0.8×	1.1k 3.3×	213 0.8×	23	2.6k

Countries citing papers authored by Jörg Schrader

Since Specialization

Citations

This map shows the geographic impact of Jörg Schrader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Schrader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Schrader more than expected).

Fields of papers citing papers by Jörg Schrader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Schrader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Schrader. The network helps show where Jörg Schrader may publish in the future.

Co-authorship network of co-authors of Jörg Schrader

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Schrader. A scholar is included among the top collaborators of Jörg Schrader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Schrader. Jörg Schrader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ungefroren, Hendrik, Harpal Randeva, Hendrik Lehnert, et al.. (2025). Crosstalk of TGF-β and somatostatin signaling in adenocarcinoma and neuroendocrine tumors of the pancreas: a brief review. Frontiers in Endocrinology. 16. 1511348–1511348. 1 indexed citations

Johnson, Jeremy A., Aman Chauhan, Jong Cheol Jeong, et al.. (2024). Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor. Cancer Letters. 596. 216993–216993. 5 indexed citations

Briest, Franziska, Liliana H. Mochmann, Helma Freitag, et al.. (2024). Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells. Frontiers in Pharmacology. 15. 1308686–1308686. 2 indexed citations

Ascione, Frank J., Franco Fedeli, Jörg Schrader, et al.. (2024). The Novel SSTR3 Full Agonist ITF2984 Shows Antitumor Properties against Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 115(5). 446–459.

Amin, Tania, et al.. (2023). Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?. Endocrine. 83(2). 511–518. 5 indexed citations

April-Monn, Simon, Daniel Helbling, Massimo Falconi, et al.. (2022). Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects. Cancers. 14(22). 5481–5481. 5 indexed citations

Ungefroren, Hendrik, Axel Künstner, Hauke Busch, et al.. (2022). Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling. International Journal of Molecular Sciences. 23(24). 15868–15868. 7 indexed citations

Krug, Sebastian, Jens Walldorf, Philipp A. Reuken, et al.. (2022). The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease. Cancers. 14(3). 613–613. 2 indexed citations

Feng, Zijie, Xin He, Xuyao Zhang, et al.. (2022). Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nature Cancer. 3(5). 581–594. 69 indexed citations

10.

Ehlken, Hanno, Rüdiger Schmitz, Sabine Riethdorf, et al.. (2021). Possible tumour cell reimplantation during curative endoscopic therapy of superficial Barrett’s carcinoma. Gut. 71(2). 277–286. 1 indexed citations

11.

Bell, Jessica L., Stefan Hüttelmaier, Till S. Clauditz, et al.. (2021). Targeting HDACs in Pancreatic Neuroendocrine Tumor Models. Cells. 10(6). 1408–1408. 17 indexed citations

12.

Rinke, Anja, Thomas M. Gress, Jörg Schrader, et al.. (2021). Clinical Features and Prognosis of Patients with Carcinoid Syndrome and Carcinoid Heart Disease: A Retrospective Multicentric Study of 276 Patients. Neuroendocrinology. 112(6). 547–554. 13 indexed citations

13.

Fehrenbach, Uli, Antonin Kayser, Ulrich‐Frank Pape, et al.. (2021). Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 112(6). 595–605. 3 indexed citations

14.

Krug, Sebastian, et al.. (2020). Professional Assessment of the Impact of COVID-19 on Handling NET Patients. Journal of Clinical Medicine. 9(11). 3633–3633. 7 indexed citations

15.

Luley, Kim Barbara, Axel Künstner, Hauke Busch, et al.. (2020). A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1. Cancers. 12(3). 691–691. 34 indexed citations

16.

Benten, Daniel, Gerrit Wolters‐Eisfeld, Susanne Burdak‐Rothkamm, et al.. (2018). Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. Molecular Cancer Research. 16(3). 496–507. 54 indexed citations

17.

Spöttl, Gerald, Julian Maurer, Michael Lauseker, et al.. (2018). The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocrine Related Cancer. 25(10). 893–908. 19 indexed citations

18.

Nölting, Svenja, Helma Freitag, Katharina Detjen, et al.. (2017). The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PLoS ONE. 12(8). e0182852–e0182852. 28 indexed citations

19.

Lüth, Stefan, Jörg Schrader, Antonella Carambia, et al.. (2011). Chronic Inflammatory IFN-γ Signaling Suppresses Hepatocarcinogenesis in Mice by Sensitizing Hepatocytes for Apoptosis. Cancer Research. 71(11). 3763–3771. 25 indexed citations

20.

Huber, Samuel, Felix R. Stahl, Jörg Schrader, et al.. (2009). Activin A Promotes the TGF-β-Induced Conversion of CD4+CD25− T Cells into Foxp3+ Induced Regulatory T Cells. The Journal of Immunology. 182(8). 4633–4640. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact